[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Huons Biopharma\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100531899","phase-3-to-evaluate-hu-045-in-the-treatment-of-glabellar-linesphase-iii-100531899",false,"NCT06205797","To Evaluate HU-045 in the Treatment of Glabellar Lines(Phase III)","A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase III Clinical Trial to Evaluate the Efficacy and Safety of HU-045 Compared to Xeomin® in Adult Patients With Moderate or Severe Glabellar Lines","Inclusion Criteria:\n\n* 19 Years to 65 Years(Adult, Older Adult)\n* 2(Moderate) and\u002For above of Facial Wrinkle Scale (FWS) score at frown in investigator's live assessment.\n* Subject who signed voluntarily in informed consent form and fully understood about this clinical trial.\n\nExclusion Criteria:\n\n* Subject who has history of any diseases following. (myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis etc.)\n* History of bleeding disorder\n* Infection, dermatological condition or scar at the treatment injection sites\n* Subject who has marked facial asymmetry\n* History of facial nerve palsy or eyebrow\u002Feyelid ptosis\n* History of surgical procedures affecting on the lines of forehead and\u002For middle of the forehead areas\n* History of malignant tumor within 5 years (except for basal cell carcinoma\n* Any disease and condition that, in the view of the investigator, would interfere with study participation\n* History of alcohol or drug addiction\n* Subject who has been treated with any botulinum toxin drug within 6 months\n* Persons who have received the following drugs with systemic muscle relaxant action within 4 weeks of screening\n* Subjects taking more than 1,000 IU\u002Fday of anticoagulants, antiplatelet agents, NSAIDs, or vitamin E within 7 days prior to administration of the investigational drug (excluding low-dose aspirin)\n* A person who has received a retinoid series of medications during the following period as of the time of screening\n* Subjects who have hypersensitivity reaction to investigational drug or local anesthetics\n* History of Anaphylaxis or severe combined allergy disease\n* Subject who has physically untreatable glabellar lines like that can't be spread out even if someone forces it to spread out\n* Pregnant and lactating women F- ertile women and men who have plans to pregnancy and who do not agree to appropriate contraception.\n* Participant who has been treated with any investigational drug within 30 days from screening\n* Subject who are not eligible for this study based on investigator's judgement.",true,"ALL","19 Years","65 Years",{"count":21,"type":22},312,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HU-045 and Xeomin® in Patients With Moderate to Severe Glabellar Lines",[28],"Glabellar Lines","RECRUITING","2024-10-01",{"date":32,"type":33},"2024-10-03","ACTUAL",{"date":35,"type":33},"2024-06-20",{"date":37,"type":22},"2025-03-31",{"name":39,"class":40},"Huons Biopharma","INDUSTRY",""]